In February 2024 after receiving details of the genetic sequence of the coronavirus, Inovio announced that it had produced a preclinical DNA-based vaccine as a potential therapy for COVID-19. Inovio is in competition to develop a coronavirus vaccine with numerous other companies, which were conducting preclinical or early-stage human research on more than 170 vaccine candidates, as of late June. In April 2024, Inovio began a Phase I trial of the COVID-19 vaccine ca… Web44 minutes ago · KANSAS CITY, Mo. ( WDAF) — A teenager is recovering after being shot outside of a Kansas City, Missouri, home Thursday evening. Police believe it was a case of …
Inovio says COVID-19 vaccine candidate safe, effective in
Web1 day ago · A COVID and flu combination shot could also lead the public to believe both viruses are similarly dangerous. While categorically untrue in 2024, such a shift in … WebMay 11, 2024 · Inovio also announced on Wednesday it would discontinue work on its Covid-19 vaccine and will shift its focus to developing a booster. Replacing Kim as Inovio's president and CEO is Jacqueline ... texaspeacemaker
Inovio Embroiled in Lawsuits Around Its Potential COVID-19 Vaccine
WebApr 23, 2024 · April 23 (Reuters) - Inovio Pharmaceuticals (INO.O) said on Friday the U.S. government pulled the funding for a late-stage study testing its COVID-19 vaccine candidate and that it would now... WebOct 27, 2024 · SilverV. Inovio Pharmaceuticals (NASDAQ:INO) on Thursday said it had discontinued development of its COVID-19 booster vaccine.Shares of the small-cap biotech fell 2.4% to $2.01 after hours. "The ... WebMar 1, 2024 · (Reuters) - U.S. vaccine developer Inovio Pharmaceuticals Inc said on Monday it had completed Phase II enrolment for a mid-to-late stage U.S. trial of its COVID-19 … texasplatinumorgional